

London Cancer Gynaecology Tumour Pathway Board Annual Report 2017-18

Introduction

London Cancer incorporates the geographical areas of North Central and East London and West Essex with a population of 3.7 million. Since 2016, *London Cancer* has become one of the six principal programmes of the UCLH Cancer Collaborative.

The Gynaecology Tumour Pathway Board is a cancer specific board led by Alex Lawrence, Tumour Pathway Director. The board is responsible for driving improvement across the whole care pathway in a specific cancer type. The Board's membership includes multi-disciplinary representation from cancer professionals across the region and active participation from primary care and from patients.

The role of each pathway board is to understand any variation in practice and set standards that take advantage of planning whole pathways of cancer care for a large population. This drive to improve cancer care for patients covers an integrated care pathway that extends from presentation and diagnosis through to palliative care and living with and beyond cancer.

Alexandra Lawrence, Consultant Gynaecological Surgeon at Barts and the Royal London Hospital took up the role of Pathway Director in July 2017, succeeding Mr Tim Mould, Consultant Gynaecological Oncological Surgeon, UCLH.

Achievements this year

This year we have had a focus on streamlining the cancer pathways within our network and reducing the variation of care given across the UCLH Cancer Collaborative trusts.

Our key achievements have been:

- Engagement of ultrasonographers and radiologists in IOTA simple rules quality improvement.
- A Gynaecology Research day in April 2017 that had excellent feedback, particularly about the speakers and the event organiser, Michelle Lockley.
- An audit of lymphoedema provision across *London Cancer*.
- Disseminated job description for MDT chair to aid MDT improvement.
- *London Cancer* Gynaecology Annual Education open meeting in October 2017 had over 40 attendees and feedback was very positive.

Patient representation

We are grateful to have Patricia Jupp and Susan Boyde as patient representatives.



Alexandra Lawrence, Gynaecology Pathway Board Director, Consultant Gynaecological Surgeon at Barts Health

UCLH Cancer Collaborative brings together hospital trusts, GPs, health service commissioners, local authorities and patients across north and east London and west Essex.

Patricia Jupp, one of the patient representatives, looks back on the approach taken with patient representation on the Pathway Board:

"With patient involvement not being quite as actively encouraged these days as it used to be in the past, I was quite taken aback by the reaction of Alex, the Pathway Board's new Director, when I sent her apologies for a meeting because I found the venue too difficult to access. She not only appreciated my problem, but promptly asked for the rest of the meetings to be moved to a venue that would be accessible for me. I was very pleased to think that Alex should appreciate the patient presence sufficiently to take such action. Thank you, Alex! "

Future plans

Our 2017/18 work plan is outlined below:

No	Objective	By
1	Early and faster diagnosis: <ul style="list-style-type: none"> Quality improvement in ultrasound with use of IOTA simple rules. Hold education days that will be open to <i>London Cancer</i> gynaecological ultrasonographers and radiologists. Increase screening uptake. Implementing stratified follow-up. 	April 2019
2	Wider system engagement: <ul style="list-style-type: none"> Hold the annual <i>London Cancer</i> Gynaecology Research Day in April 2018. Annual Gynaecology education event. CNS subgroup led by Karen Summerville. 	April 2018 April 2019 Ongoing
3	Updating clinical guidelines and conducting system audits: <ul style="list-style-type: none"> System audit of ultrasound quality. 	April 2019
4	Research: <ul style="list-style-type: none"> Continue recruitment into NCRI badged clinical trial recruitment and use of North Thames CRN data with Pathway Board to drive improvement and cross-sector working. Develop a regular newsletter for trials. 	Ongoing
5	Data and outcomes: <ul style="list-style-type: none"> Promote the use of MDT scorecards. Review data available through the pan-Vanguard informatics service regularly to offer clinical interpretation and quality assurance. 	Ongoing
6	Patient experience: <ul style="list-style-type: none"> Review national patient survey report and develop action plan as necessary. 	March 2019
7	MDT improvement: <ul style="list-style-type: none"> Increase the number of staged cancers at MDT meetings. 	March 2019

Acknowledgements

We would like to thank all the members of the Gynaecology Tumour Pathway Board for contributing their time to Tumour Pathway Board meetings and projects outside the meeting.

Particular thanks to our patient representatives Patricia Jupp and Susan Boyde who have generously given up their time to contribute.